ReNewVax Offering  

Convertible Redeemable Preference Shares


Reporting Currency

Use of funds




Pound Sterling


Sector Biotech – vaccines
Key Market Data  
Market Private Offering
Price per Share €1
Number of shares for sale 3,000,000
Total €3,000,000.00
Company Value €29,000,000

15% Compounded

5 years

Fiscal Year end 31st December
Company Objective Growth

Main Shareholders


University of Liverpool 37%

Management Team 60%

ReNewVax 15 % cumulative redeemable preference share offering.


ReNewVax’s stated aim is to prevent life-threatening bacterial infections and combat antimicrobial resistance with vaccines. ReNewVax is a next generation vaccine company developing therapeutic vaccines targeting some of the world’s most acute bacterial disease challenges.

Spun out of the University of Liverpool (UoL) to commercialise the intellectual property generatedfrom the work of Dr Marie Yang and Professor Aras Kadioglu, exploiting a reverse vaccinology strategy, ReNewVax is deploying genomic-led, rational discovery approaches to produce a pipeline of programs that offer protection beyond existing traditional vaccines, which opens up access and delivers a step-change in global health security.